^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    STI-8591

    i
    Other names: STI-8591
    Company:
    Sorrento
    Drug class:
    FLT3 inhibitor
    Related drugs:
    11ms
    A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=84, Recruiting, Zhejiang ACEA Pharmaceutical Co. Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    STI-8591
    12ms
    A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=84, Not yet recruiting, Zhejiang ACEA Pharmaceutical Co. Ltd. | Initiation date: Sep 2023 --> Mar 2024
    Trial initiation date • Metastases
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    STI-8591
    over1year
    A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
    P1, N=84, Not yet recruiting, Zhejiang ACEA Pharmaceutical Co. Ltd.
    New P1 trial • Metastases
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    STI-8591